File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: An electroporation platform for Erlotinib resistance screening in living non-small cell lung cancer (NSCLC) cells

TitleAn electroporation platform for Erlotinib resistance screening in living non-small cell lung cancer (NSCLC) cells
Authors
KeywordsCell mechanics
Drug-resistance
Electroporation
Nano-indentation
Issue Date2018
PublisherInstitute of Physics Publishing Ltd. The Journal's web site is located at http://iopscience.iop.org/2057-1976
Citation
Biomedical Physics & Engineering Express, 2018, v. 4 n. 2, article no. 027001 How to Cite?
AbstractAn electroporation device was developed to introduce transient membrane pores and, consequently, enhance membrane permeability in living cells in a controllable manner. The validity of this platform was assessed on six non-small cell lung cancer (NSCLC) cell lines using different fluorescent dyes. Interestingly, it was found that the electroporation efficiency of these cells, i.e. the percentage of cells with membrane pores created, decreases significantly (from ~60% to 30%) as their resistivity against Erlotinib increases, demonstrating the potential of such approach as a screening tool for assessing drug resistance in tumours in the future. Furthermore, we showed that the inverse relationship between the electroporation efficiency and Erlotinib resistance is likely due to the fact that NSCLC cell lines with higher drug resistivity appear to have lower cortical tensions and hence make it harder for membrane pores to be created, consistent with existing electroporation theories.
Persistent Identifierhttp://hdl.handle.net/10722/264187
ISSN
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorYan, Z-
dc.contributor.authorHui, TH-
dc.contributor.authorFong, HW-
dc.contributor.authorShao, X-
dc.contributor.authorCho, WC-
dc.contributor.authorNgan, KC-
dc.contributor.authorYip, TC-
dc.contributor.authorLin, Y-
dc.date.accessioned2018-10-22T07:50:56Z-
dc.date.available2018-10-22T07:50:56Z-
dc.date.issued2018-
dc.identifier.citationBiomedical Physics & Engineering Express, 2018, v. 4 n. 2, article no. 027001-
dc.identifier.issn2057-1976-
dc.identifier.urihttp://hdl.handle.net/10722/264187-
dc.description.abstractAn electroporation device was developed to introduce transient membrane pores and, consequently, enhance membrane permeability in living cells in a controllable manner. The validity of this platform was assessed on six non-small cell lung cancer (NSCLC) cell lines using different fluorescent dyes. Interestingly, it was found that the electroporation efficiency of these cells, i.e. the percentage of cells with membrane pores created, decreases significantly (from ~60% to 30%) as their resistivity against Erlotinib increases, demonstrating the potential of such approach as a screening tool for assessing drug resistance in tumours in the future. Furthermore, we showed that the inverse relationship between the electroporation efficiency and Erlotinib resistance is likely due to the fact that NSCLC cell lines with higher drug resistivity appear to have lower cortical tensions and hence make it harder for membrane pores to be created, consistent with existing electroporation theories.-
dc.languageeng-
dc.publisherInstitute of Physics Publishing Ltd. The Journal's web site is located at http://iopscience.iop.org/2057-1976-
dc.relation.ispartofBiomedical Physics & Engineering Express-
dc.rightsBiomedical Physics & Engineering Express. Copyright © Institute of Physics Publishing Ltd.-
dc.rightsThis is an author-created, un-copyedited version of an article published in Biomedical Physics & Engineering Express. IOP Publishing Ltd is not responsible for any errors or omissions in this version of the manuscript or any version derived from it. The Version of Record is available online at http://dx.doi.org/10.1088/2057-1976/aa99e9.-
dc.subjectCell mechanics-
dc.subjectDrug-resistance-
dc.subjectElectroporation-
dc.subjectNano-indentation-
dc.titleAn electroporation platform for Erlotinib resistance screening in living non-small cell lung cancer (NSCLC) cells-
dc.typeArticle-
dc.identifier.emailLin, Y: ylin@hkucc.hku.hk-
dc.identifier.authorityLin, Y=rp00080-
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.doi10.1088/2057-1976/aa99e9-
dc.identifier.scopuseid_2-s2.0-85043495301-
dc.identifier.hkuros293956-
dc.identifier.volume4-
dc.identifier.issue2-
dc.identifier.spagearticle no. 027001-
dc.identifier.epagearticle no. 027001-
dc.identifier.isiWOS:000434518200045-
dc.publisher.placeUnited Kingdom-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats